Inspire Medical Systems, Inc.(INSP) Stock Research - Grey Stern Research
Loading...

Inspire Medical Systems, Inc. (INSP) Stock Analysis

$160.94 (-1.38%)

INSP Financial Performance


Use the table below to view Inspire Medical Systems, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $160.94 -
52 Week Low $123.00 -
52 Week High $257.40 -
Market Cap $4.8 Billion 7/14
Gross Margin 85% 3/14
Profit Margin 15% 4/14
EBITDA margin 24% 2/14
Q4 - 2024 Revenue $239.7 Million 6/14
Q4 - 2024 Earnings $35.2 Million 5/14
Q4 - 2024 Free Cash Flow $62.2 Million 3/14
Trailing 4 Quarters Revenue $802.8 Million 6/14
Trailing 4 Quarters Earnings $53.5 Million 6/14
Quarterly Earnings Growth 139% 1/14
Annual Earnings Growth 593% 1/14
Quarterly Revenue Growth 25% 5/14
Annual Revenue Growth 23% 6/14
Cash On Hand $150.2 Million 10/14
Short Term Debt $0 12/14
Long Term Debt $30.0 Million 10/14

Inspire Medical Systems, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Inspire Medical Systems, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 89.51 3/14
PS 5.97 8/14
PB 6.94 10/14
PC 31.90 6/14
Liabilities to Equity 0.17 13/14
ROA 0.07 5/14
ROE 0.08 6/14
Current Ratio 6.81 2/14
Quick Ratio 3.75 2/14
Long Term Debt to Equity 0.04 12/14
Debt to Equity 0.04 13/14
Burn Rate -4.41 10/14
Cash to Cap 0.03 9/14
CCR 1.76 2/14
EV to EBITDA 82.27 7/14
EV to Revenue 5.82 8/14

Company Details

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

CEO: Mr. Timothy Herbert

Website: https://www.inspiresleep.com

Address: 5500 Wayzata Blvd Ste 1600 Golden Valley, MINNESOTA

Exchange: New York Stock Exchange

Industry: Medical Devices

Inspire Medical Systems, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Inspire Medical Systems, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Glaukos Corporation GKOS $5.9 Billion
Tandem Diabetes Care, Inc. TNDM $1.3 Billion
DexCom, Inc. DXCM $27.1 Billion
Insulet Corporation PODD $18.3 Billion
NovoCure Limited NVCR $2.1 Billion
Globus Medical, Inc. GMED $11.8 Billion
Penumbra, Inc. PEN $10.4 Billion
InMode Ltd. INMD $1.3 Billion
ShockWave Medical, Inc. SWAV $12.6 Billion
TransMedics Group, Inc. TMDX $2.4 Billion
ClearPoint Neuro, Inc. CLPT $343.2 Million
Inari Medical, Inc. NARI $4.7 Billion
Outset Medical, Inc. OM $214.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
INSP Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 239.7 Million $35.2 Million
Q3 2024 $ 203.2 Million $18.5 Million
Q2 2024 $ 195.9 Million $9.8 Million
Q1 2024 $ 164.0 Million -$10.0 Million
Q4 2023 $ 192.5 Million $14.8 Million
Q3 2023 $ 153.3 Million -$8.5 Million
Q2 2023 $ 151.1 Million -$12.0 Million
Q1 2023 $ 127.9 Million -$15.4 Million

View All

INSP Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $150.2 Million $808.4 Million $30.0 Million $689.7 Million
Q3 2024 $147.5 Million $796.2 Million $25.2 Million $696.6 Million
Q2 2024 $188.0 Million $728.4 Million $24.5 Million $638.1 Million
Q1 2024 $175.4 Million $685.8 Million $24.5 Million $589.0 Million
Q4 2023 $185.5 Million $676.8 Million $24.8 Million $572.5 Million
Q3 2023 $329.9 Million $639.5 Million $25.2 Million $544.2 Million
Q2 2023 $467.1 Million $618.2 Million $22.1 Million $529.4 Million
Q1 2023 $442.1 Million $571.8 Million $7.2 Million $504.6 Million

View All

INSP Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 $62.2 Million -$7.0 Million $2.6 Million
Q3 2024 $44.3 Million -$8.0 Million -$40.5 Million
Q2 2024 -$12.5 Million -$12.4 Million $12.6 Million
Q1 2024 -$2.8 Million -$11.7 Million -$10.1 Million
Q4 2023 $9.2 Million -$8.0 Million -$144.4 Million
Q3 2023 -$3.4 Million -$7.0 Million -$137.2 Million
Q2 2023 $237,000 -$4.9 Million $24.9 Million
Q1 2023 -$5.1 Million -$3.8 Million $540,000

View All